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Examining the mechanistic roles of Integrin Alpha-6 in cancer metastasis. 
  




Chase Clark  
Under the mentorship of Dr. Vinoth Sittaramane. 
  
 ABSTRACT 
Metastasis- the spread of cancer cells from the primary tumor to the 
surrounding tissues- is responsible for 90% of cancer deaths. Integrin alpha-6 (ITGA6) 
is a specific transmembrane cell surface protein that functions in cell surface adhesion 
and signaling. ITGA6 is upregulated in many types of cancers and promotes the 
migration and invasion of cancer cells to surrounding tissues. It is my objective to 
determine the mechanism through which ITGA6 facilitates the migration of cancer 
cells through the extracellular matrix (ECM). These experiments helped to establish the 
role of ITGA6 in tumor development and provide focus for possible chemotherapeutic 
treatment.  Using an in-vitro cell migration assay I observed the varying rates of 
invasion through the ECM by PC3 cancer cells transfected to express various amounts 
of ITGA6. High-resolution imaging techniques were used in coordination with cell 
counting software to examine the number of PC3 cells that had migrated across the 
laminin-coated membrane. I found that PC3 cells with ITGA6 knockdown had lower 
rates of cell migration compared to untreated PC3 cells while PC3 cells with ITGA6 
overexpression had the greatest rate of invasion through the ECM. Based on my 
findings, future studies can aim to identify possible alternative pathways of ITGA6 
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Cancer is a highly complex and variable disease caused by a malfunctioning of 
our own cells. There are many different types of cancer, but they all share a common 
feature of unregulated proliferation. Normally, the division of cells is a highly regulated 
and controlled cycle; however, cancer cells develop a mutation in their cell cycle 
allowing them to replicate unimpeded. Cancer arises from a mutated gene known as an 
oncogene which in certain circumstances can transform a normal cell into a tumor cell. 
Abnormal cells that do not function properly normally undergo apoptosis and are 
replaced, but certain mutations can allow these cells to bypass this mechanism.  
Cancers develop and evolve 
through clonal expansion and clonal 
selection of abnormal cells. The 
accumulation of mutations gives cancers 
unique traits including resistance to anti-
growth signals, evading apoptosis, inducing 
angiogenesis, tissue metastasis, and more 
(Hanahan & Weinberg, 2011). Of these, 
cancer metastasis is of leading concern. 
According to statistics published by the 
National Cancer Institute in 2016, 
approximately 455 people per 100,000 are 
at risk of developing cancer, and of these 455 people, 171 will die because of it. Of these 
cancer deaths, it is estimated that approximately 90% are caused by metastasis. Creating 
efficient cancer diagnostic techniques as well as developing targeted cancer therapeutic 
treatments is of greatest concern within the field of cancer research. Cancer metastasis is 
increasingly fatal because as secondary tumors initiate and grow in different 
tissues/organs they interrupt the body's normal physiologic function which can lead to 
organ failure. Cancer researchers are focused on investigating the biological pathways of 
cells and the mechanisms of tumorigenesis. Understanding the mechanisms that initiate 
Figure 1. The hallmarks of cancer; the acquired 
mutations of abnormal cells that contribute to 
the development of a tumor (Hannan & 
Weinberg, 2011). 
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and facilitate cancer cell metastasis is of high priority in order to identify potential drug 
targets to prevent cancer metastasis, giving cancer patients better prognoses. 
  
Integrins 
Studies by Itou et al. in 2017 suggest that integrins play an important role in cell 
migration. Integrins are transmembrane proteins that function mechanically by attaching 
the cell cytoskeleton to the extracellular matrix (ECM). The integrin molecule is 
composed of two transmembrane glycoprotein subunits; alpha(α) and beta(β). The 
formation of a heterodimer between the alpha and beta subunits forms an integrin that 
interacts with extracellular matrix proteins, including laminin family proteins. There are 
24 different types of integrin proteins in 
mammals, determined by the different 
combinations of alpha and beta subunits. With 
specific functions, these integrins create a bridge 
between the ECM and cytoskeleton of cells to 
detect changes in the environment, enabling cells 
to react to external signals. Integrins are involved 
in multiple developmental processes including 
cell differentiation, cell adhesion, cell migration, 
and cell proliferation (Bianconi, Unseld, Prager, 
2016). In cancer, malignant cells manipulate these 
functional mechanisms. 
Unlike mesenchymal cells, epithelial cells have the ability to migrate only during 
development and tissue repair. For a cancer cell to gain migratory ability, the epithelial 
cell must undergo epithelial to mesenchymal transition (EMT). Researchers are 
investigating possible mechanisms by which integrin expression facilitates EMT, 
initiating tumor invasion. The integrin subunit alpha-6 (ITGA6) has been observed to 
promote tumorigenesis; ITGA6 is a protein coding gene that encodes a family of proteins 
on the alpha-6 subunit. ITGA6 is upregulated in many types of cancers (Figure 3) and 
has been shown to promote the migration and invasion of cancer cells to surrounding 
tissues, but the functional mechanism remains unclear. In 2019, researchers used mass 
Figure 2. Integrin Structure: composed 
of one of 18 alpha-subunits and one of 
8 beta-subunits. 
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spectrometry to find that ITGA6 was more highly expressed in a highly invasive 
pancreatic cancer cell line than compared to a less invasive cell line. They concluded that 
a higher expression of ITGA6 was correlated to a worse prognosis (Wu et al., 2019). 
Figure 3. Immunohistochemical analysis of ITGA6 expression in various cancers using the 
HPA012696 antibody. Significant numbers of patients’ cancers exhibit expression of ITGA6, including 
pancreatic cancer. Note that cancers with 0% expression do not necessarily show no ITGA6 expression, 
simply no reactivity with the specific antibody (The Human Protein Atlas). 
 
Prostate Cancer 
 The prostate gland is a reproductive organ found only in males and is located 
below the bladder and in front of the rectum. The prostate functions to secrete prostate 
fluid, a major component of semen that nourishes and protects sperm. Muscles of the 
prostate gland help to propel this seminal fluid into the urethra during ejaculation. 
Prostate cancer begins when cells 
in the prostate gland develop a 
mutation and begin to grow out of 
control. Symptoms of prostate 
cancer include trouble urinating, 
blood in semen, erectile 
dysfunction, and discomfort in the 
pelvic region. About one in 9 men 
will be diagnosed with prostate 
cancer; the majority of which are 
adenocarcinomas, cancers that 
develop from the gland cells in the glandular tubes and duct lining. The death rate of men 
Figure 4. Anatomy of the male reproductive system. The 
prostate gland is responsible for producing prostate fluid 
and projecting this seminal fluid during ejaculation. Here, 
a cancer mass in the prostate is shown in white (American 
Cancer Society, 2020).    
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diagnosed with prostate cancer is 19.1%, of which 90% can be contributed to metastasis 
(American Cancer Society, 2020). When prostate cancer metastasizes, it is likely to 
invade into the bladder or even the circulatory system where it can spread to the bones or 
other organs. Depending on the stage of cancer progression, prostate cancer is normally 
treated with surgery, radiation therapy, chemotherapy, hormone therapy, or any other 
combination of treatments.  
 
Present Study Aims and Significance 
 It was my objective to characterize the in-vitro interactions between human 
ITGA6 and human cancer, also to identify the mechanisms by which ITGA6 contributes 
to cancer metastasis. I sought to confirm my hypothesis that the decreased expression of 
ITGA6 would reduce cancer cell migration and that the increased expression of ITGA6 
would increase cancer cell migration. By determining the functional mechanism of 
ITGA6 in inducing cell migration, and by experimenting with various ITGA6 constructs, 
identification of putative biomarkers will contribute to the discovery and design of 
possible drug targets. Creating chemotherapy drugs to target mutated integrin pathways 
have the possibility of reducing cancer deaths caused by cancer metastasis.  
 
EXPERIMENTAL DESIGN 
To understand the mechanism through which ITGA6 facilitates the migration of 
cancer cells through the ECM, ITGA6 was manipulated in order to test various functional 
pathways. Through RNA/DNA transfection, prostate cancer cells (PC3) were introduced 
to various human ITGA6 RNA/DNA constructs, influencing ITGA6 expression in cancer 
cells. Injecting human full-length ITGA6 cDNA increases expression, resulting in 
overexpression of ITGA6 protein. SiRNA transfection to knockdown the ITGA6 gene 
results in the decreased expression of ITGA6 protein. Injecting human truncated ITGA6 
DNA results in the expression of cleaved ITGA6- free floating extracellular ITGA6 
domains. Injecting human mutated ITGA6 DNA results in the expression of a non-
cleavable ITGA6 protein. Applying these different ITGA6 constructs to PC3 cells and 
conducting in-vitro tests will provide insight into the mechanism by which ITGA6 
contributes to cell migration.  
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Beginning with cultured prostate cancer (PC3) cells, the cells were split into 
different experimental groups transfected with different ITGA6 constructs to manipulate 
the cells’ expression of the integrin protein. These cells were then utilized in an in-vitro 
laminin migration assay. Laminin is an extracellular matrix protein; the migration assay 
allowed us to observe the experimental groups’ abilities to migrate through the ECM 
protein, indicating cellular aggression. Analysis of the in-vitro model provided insight 
regarding the functionality of ITGA6 in cancer cell migration. 
  
METHODS 
Cell Culture: Seeding a new cell line (Thawing) 
 First, RPMI 1640 culture medium was removed from the +4ºC refrigerator and 
placed in a 37 ºC water bath for 5 minutes or until warm. During this time the Biosafety 
Cabinet (BSC) laminar flow hood was prepared and disinfected with 70% EtOH. 
Additionally, all items used in the BSC hood were disinfected with 70% EtOH before 
entering, including pipettes, falcon tubes, cell culture plates, bottle of culture medium, 
etc. Next, 20mL of warmed culture medium was pipetted into two T-75 tissue culture 
flasks. One vial of frozen PC3 cells was removed from the Liquid Nitrogen Storage 
Dewar from the vapor phase and immediately placed into the 37 ºC water bath for 2 
minutes. Once thawed the vial was sprayed with 70% EtOH and placed into the BSC 
hood. Each vial of PC3 cells contained approximately 1𝑋10! cells suspended in 1ml of 
cell culture medium with 10% Dimethyl Sulfoxide (DMSO); 500µL of the vial contents 
were pipetted into each tissue culture flask with medium. If the vial contained more than 
1mL of cells, the remainder was split between the two flasks. The flasks were then gently 
tilted back and forth to mix the cells in the medium and then placed into the 37°C CO2 
incubator. In 48 hours, the cell culture medium in each flask was removed and the flasks 
were washed with 7mL 1XPBS to remove any leftover DMSO. Then 10mL of fresh 
culture medium was added to each flask. 
  
Cell Culture: Harvesting cells 
The cell culture medium used to sustain and grow cells was made by adding 
50mL heat inactivated Fetal Bovine Serum and 5mL Penicillin/Streptomycin solution to 
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500mL of RPMI 1640 media. Phosphate buffered saline (10xPBS) was diluted to 1xPBS 
using DNase-free distilled water. Trypsin (0.05%), a serine protease, was used to 
dissociate adherent PC3 cells from the tissue-culture treated flasks. The culture medium 
and trypsin were placed a hot water bath for two minutes; during this time the BSC was 
sprayed with 70% EtOH. Once the bottles reached room temperature, they were 
disinfected along with the 1xPBS solution and placed into the BSC hood. Next, the 
desired flask of PC3 cells was removed from the 37°C CO2 incubator, sprayed with 70% 
EtOH and placed into the BSC hood. The culture medium was then vacuumed out of the 
flask - careful not to touch the adherent cells on the bottom of the treated flask. 7mL of 
1xPBS was added to the flask and tilted to allow the PBS to cover the entire treated 
surface. The 1xPBS was then vacuumed out of the flask to wash out any dead cells. 
7.5mL of trypsin was then added into the flask and incubated for 5min in the 37°C CO2 
incubator. Next the flask was viewed under a compound light microscope to visualize the 
free-floating, detached cells. The flask was then disinfected before being placed back into 
the BSC hood. 2.5mL of culture medium was then added to the flask, mixing with the 
trypsin to inhibit its protease function. The contents of the flask were then transferred into 
a 50mL Falcon centrifuge tube. The Falcon tube was centrifuged at 970rpm for 5 
minutes. The trypsin/medium solution was aspirated from the tube- careful not to vacuum 
up the mass of cells collected on the bottom of the tube. 8mL of 1XPBS was then added 
into the Falcon tube and was gently pipetted up and down to resuspend the cells. The 
Falcon tube was centrifuged again at 970rpm for 3 minutes and the PBS aspirated. 2 mL 
of fresh culture medium was added to the tube and cells resuspended. Finally, the number 
of cells were counted using a hemocytometer and the necessary concentration of cells 
needed for further experimentation was calculated. 
 
Cell Labeling 
 Following harvesting, 1× 10! cells were aliquoted into a microcentrifuge tube. 
The tube was centrifuged at 500rcf for 2 minutes. The supernatant was aspirated from the 
microcentrifuge tube and 1mL of serum-free medium was added. The cells were then 
resuspended and 5µL of DiI cell tracker (Thermo Fisher D3911) was added. A vortex 
mixer was used to mix the dye and then incubated for 30 minutes at 37°C. Following 
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incubation, the tube was re-centrifuge at 500rcf for 2 minutes. The supernatant was 
aspirated while being careful not to disturb the cell pellet. 200µL of RPMI 1640 medium 
was added and cells resuspended. The tube was incubated for another hour before 
microinjection into 2-day old zebrafish embryos. 
 
ITGA6 Transfection 
 PC3 cells were harvested at 70%-90% confluency and seeded 0.5-2× 10" cells 
per well into a 24-well tissue culture plate. The plate was incubated for 24-48 hours 
before initiating transfection. In a microcentrifuge tube 4µL of Lipofectamine3000 
reagent was diluted with 50µL of Opti-MEM medium. Stock solutions of ITGA6 siRNA 
and ITGA6 DNA were diluted to 10µM solutions. Constructs included GAPDH siRNA, 
siRNA s7492, and full-length DNA. In another microcentrifuge tube the constructs were 
diluted with 50mL of Opti-MEM and 2µL of P3000 Reagent. 2µL of GAPDH siRNA 
was used for GAPDH transfection, 2µL of siRNA s7492 was used for siRNA 
transfection, and 0.5µL of full-length DNA was used for DNA transfection. The diluted 
RNA/DNA constructs were then mixed with the diluted Lipofectamine 3000 Reagent in a 
1:1 ratio and incubated at room temperature for 10-15 minutes. 50µL of the RNA/DNA-
lipid complex was added into each well along with 0.5mL of culture medium and 
incubated for 48 hours at 37°C. The RNA/DNA-lipid complex mixture produced enough 
for two wells; the components were adjusted accordingly to account for additional 
experimental wells.  
 
Laminin Migration Assay 
 An ECM221 QCM Laminin Migration Assay (24-well, fluorometric) kit was used 
to conduct an in-vitro experiment of PC3 cell migration; the following procedure was 
adapted from the user guide: A 10µg/mL laminin coating solution was prepared for 12 
inserts by thawing one vial of laminin at room temperature for 10 minutes. The vial of 
laminin (60µL) was diluted with 6mL 1xPBS. A control of 0.5% BSA solution was 
prepared for 12 inserts by diluting 0.1mL 30% BSA with 5.9mL PBS. 0.5mL of the 
laminin solution, or 0.5 mL BSA solution for control wells, was added into the bottom of 
the receiver wells. One Boyden chamber insert was placed into each of the receiver wells 
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and left overnight in the +4ºC refrigerator to allow the inserts to coat in either the laminin 
or BSA solution.  
All assay plates and reagents were warmed to room temperature and the forceps 
sterilized with 70% ethanol. Prior to performing the assay, using the sterilized forceps, 
each coated insert was washed with 1xPBS and dipped into a 10cm tissue culture plate 
filled with PBS. Each coated insert was then transferred into a clean receiver well filled 
with 0.5mL serum-free medium containing 0.5% BSA. A cell suspension containing 0.5-
1× 10" cells/mL was prepared in chemoattractant-free media containing 0.5% BSA. 
200µL of the cell suspension was then added into each insert that was in contact with 
0.5mL serum-free medium containing 0.5% BSA. The plate was covered and incubated 
for 4-24 hours at 37°C in a CO2 incubator.  
 A 1mM Calcein-AM solution was prepared by dissolving 50µg Calcein-AM (one 
vial) with 50µL DMSO. The mixture was vortexed and briefly centrifuged. The 24-well 
receiver tray was removed from the incubator and 200µL Accutase cell-detachment 
solution was added to each well and warmed to 37°C. 1µL of the Calcein-AM solution 
was then added to the receiver well of the migration assay plate containing migrated cells 
and incubated for 15 minutes at 37°C. Next, the medium from the upper chamber of the 
well was removed and each insert placed into a separate well containing the Accutase 
cell-detachment solution. The assay plate was incubated for 30 minutes at 37°C. 100µL 
of each detached cell solution was transferred into the 96 well Black Quantitation Plate 
and the fluorescent cells viewed under wavelengths of 494/517 nm. 
 
Cell Counting 
 The computer program “ImageJ” was used to quantify the number of migratory 
cells from the Laminin migration assay. Images of the assay results were uploaded to the 
program as a pdf and converted to an 8-bit file, making the image black and white: 
[Type]->[8-bit]. Then the contrast threshold between the white cells and the black 
background was adjusted to clarify the image: [Adjust]-> [Threshold]. Next, the cells that 
appeared to be clumped together were separated: [Binary]->[Watershed]. Finally, the 
number of cells were quantified: [Analyze]-> [Analyze Particles]. The minimum pixel 
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Cultured PC3 cells that had been radioactively labeled with DiI were loaded into 
the Nanoject II Auto-Nanoliter Injector. The injection needles were loaded with the 
labeled cells and mineral oil- which served as a pressure gradient. 2-day old zebrafish 
embryos were treated with 0.04% Tricaine, an anesthetic, and the embryos injected in the 
perivitelline space. After injection, the embryos were washed three times in E3 embryo 
medium to remove any remnant anesthetic. Next, the embryos were subjected to 
Laminin, the human ECM protein. Following incubation, the zebrafish embryos were 
mounted to be used for confocal microscopy imaging. The mounted embryos were placed 
on the laser confocal and visualized for the radioactive cancer cells within the embryo. 
Using the ZEN software, the cancer cells within each embryo were imaged for a set 
amount of time and individual cancer cell migration was tracked.   
 
RESULTS AND DISCUSSION 
Expression of ITGA6 in PC3 cells 
 Integrin Alpha 6 has been shown to be expressed in multiple different cancers, 
including pancreatic cancer. In order to confirm the expression of ITGA6 in the PC3 cell 
line, non-manipulated control cells were fixed and stained using a primary ITGA6 
antibody from Life Technologies. Fixation with a secondary antibody marked with green 
fluorescent protein (Alexa Fluor 488) was used to visualize the ITGA6 in cells. 
Immunostaining and imaging revealed that the PC3 cell line constitutively expresses 
ITGA6. Their expression of ITGA6 was utilized for all experimental procedures and also 
employed as control cells, expressing moderate amounts of ITGA6 (Williams, 2018).  
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Figure 1. ITGA6 expression was visualized in the PC3 cell line via immunohistochemical analysis using a 
primary ITGA6 antibody and secondary antibody with GFP. A) Control PC3 cells were not stained thus do 
not exhibit GFP. B) PC3 cells were fixed and labeled with primary and secondary antibody and exhibit 
GFP (Williams, 2018). 
 
 
siRNA Transfection Reduces ITGA6 Expression 
 In order to determine the effectiveness of siRNA on reducing the expression of 
ITGA6, a comparative CT analysis was performed. In order to make any conclusion 
regarding the hypothesis that lower levels of ITGA6 reduce cellular metastasis, the 
functionality of implemented siRNA needed to be confirmed. Two siRNA with different 
ITGA6 targets were employed in transfection: s7492 and s7493. Results from the CT 
analysis showed that both siRNA was able to reduce the expression of ITGA6 in PC3 

















Figure 2. Comparative CT analysis indicated that both s7492 siRNA (orange) and s7493 siRNA (black) are 
able to reduce the expression of ITGA6 in PC3 cells. The positive control, GAPDH siRNA (magenta), did 




Laminin Migration Assay 
 Small interfering RNA s7492 functions to interfere with the translation of the 
integrin subunit alpha 6. To confirm the hypothesis that decreased expression of ITGA6 
reduces the ability of cancer cells to metastasize, an in-vitro laminin migration assay was 
performed. PC3 cells were harvested from the stock cell line and transfected with siRNA 
s7492 while cells transfected with GAPDH siRNA served as a positive control to 
transfection; both were normalized to an untreated control group. After transfection and 
cell harvesting, 1.0𝑋10" cells of each group were added to both Laminin and BSA 
coated inserts. BSA coated wells served as a negative control to cell migration. GAPDH 
siRNA transfected cells and control cells were run in duplicate in both Laminin and BSA 
coated inserts while siRNA s7492 transfected cells were run in triplicate in both Laminin 
and BSA coated inserts.  
To further define the role of ITGA6 in cancer cell migration, ITGA6 full-length 
cDNA was transfected into PC3 cells to investigate the hypothesis that an increased 
expression of ITGA6 increases the ability of cancer cells to metastasize. Cells transfected 
with FL-cDNA will express a greater amount of ITGA6 compared to control cells that 
express a moderate level of ITGA6. Another in-vitro laminin migration assay was 
performed following the transfection of PC3 cells with FL-DNA, siRNA s7492, and 
GAPDH siRNA. These groups were normalized to an untreated control group of PC3 
cells. Due to varying levels of cell viability after transfection, the following cell counts 
were used for the migration assay: 9.0𝑋10# FL-DNA cells, 2.2𝑋10$ siRNA s7492 cells, 
5.0𝑋10$ control cells, and 5.0𝑋10# GAPDH siRNA cells. For the migration assay 
procedure there was one set of FL-DNA experimental wells, three sets of s7492 
experimental wells, one set of untreated control wells, and one set of GAPDH control 
wells. Laminin coated wells were compared to the negative control, BSA coated wells. 
 
Table 1. The raw data from the migration assay (ECM221 QCM Laminin Migration Assay (24-well, 
fluorometric) indicating the number of migratory cells invading through the laminin coated wells and the 
BSA coated wells. Laminin coated wells mimic the basal lamina of the ECM in vertebrates while BSA 
coated wells served as a negative control to migration. Control and GAPDH cells were run in duplicate 
while ITGA6 knockdown cells were run in triplicate in Trial 1; ITGA6 overexpression was not tested. In 
trial 2 only ITGA6 knockdown cells were run in triplicate as a result of limited cell numbers. Note that the 
number of cells seeded for migration varied between groups and trials.  
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  Trial 1 Trial 2 
 Cell group BSA Laminin BSA Laminin 
control 14 cells / 38 cells 231 cells/ 545 cells 2 cells 527 cells 
GAPDH  10/69 588/970 0 12 
ITGA6 knockdown 0/19/0 80/296/37 0 197/195/158 
ITGA6 overexpression - - 0 84 
 
 
The untreated control cells experienced normal levels of migration while the s7492 
transfected cells experienced 31.9% less migration. The cells transfected with siRNA 
s7492 had a reduced expression of the ITGA6 gene, suggesting a positive correlation 
between the amount of ITGA6 expressed and the ability to metastasize. 
 
Table 2. The average percentage of migratory PC3 cells for both trials of the migration assay (ECM221 
QCM Laminin Migration Assay (24-well, fluorometric). Laminin coated wells mimic the basal lamina of 
the ECM in vertebrates while BSA coated wells served as a negative control to migration.  
 Cell group BSA Laminin 
control 1.3𝑥10%$	% 0.72% 
GAPDH 1.9	𝑥10%$ 0.51 
ITGA6 knockdown 4.8	𝑥10%" 0.49 





Figure 3. A bar graph of the average percentage of migratory PC3 cells for both trials of the migration 
assay (ECM221 QCM Laminin Migration Assay (24-well, fluorometric) in the Laminin coated wells. 
ITGA6 knockdown cells exhibited the least amount of expression, followed by the control PC3 cells, and 
then the ITGA6 overexpression cells which exhibited the greatest amount of migration. Note that the 



































The percentage of migratory cells was calculated by dividing the number of cells that had 
migrated through the Laminin or BSA coated inserts by the total number of seeded cells 
and multiplied by one hundred (Table 2). The siRNA transfected cells provided 
consistent results that the knockdown of ITGA6 reduces PC3 cell migration. ITGA6 
knockdown decreased cell migration by 0.23% compared to control PC3 cells. My 
hypothesis that an increased expression of ITGA6 would increase cellular metastasis was 
supported by the evidence that the FL-DNA transfected cells experienced a 0.21% 
increase in migration compared to control PC3 cells; However, there are multiple 
constraints within the experimental setup. During the transfection procedure, a 
considerable amount of cell death was noticed for the ITGA6 FL-cDNA cells, 
presumably due to the addition of too much DNA. Due to the limited number of cells, the 
number of cells used for the migration assay was not consistent between groups. 
Additionally, it is possible that the FL-cDNA transfected into the PC3 cells did not take, 
providing inaccurate results concerning the percentage of migratory cells.  
 
FUTURE RESEARCH 
Integrin Alpha 6 expression has been associated with metastasis in multiple 
different cancers, specifically prostate cancer. The decreased expression of ITGA6 in 
PC3 cells via siRNA transfection reduced the ability of cancer cells to migrate in-vitro. 
Furthermore, the increased expression of ITGA6 in PC3 cells via FL-cDNA transfection 
increased the ability of cancer cells to metastasize, to a slight extent. Further trials with 
ITGA6 FL-cDNA transfected PC3 cells need to be repeated to collect additional data 
regarding increased migration. Similar in-vitro experiments should be performed with 
various truncated and cleaved forms of ITGA6 to identify the functional unit controlling 
ECM remodeling, thus facilitating the delamination and migration of cancer cells. In-vivo 
experiments using zebrafish would strengthen any additional results collected from in-
vitro experimentation and serve as a basic proxy compared to a human system. A better 
understanding of the functional mechanism by which ITGA6 initiates and facilitates 
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